Study: No benefit from intermittent therapy in prostate cancer

04/4/2013 | HealthDay News

Patients with metastatic prostate cancer who received intermittent androgen deprivation therapy had a 10% greater risk of mortality than those who got continuous hormone treatment, according to a study published in the New England Journal of Medicine. Researchers tracked more than 1,500 patients and found average survival rates of 5.8 years for the continuous therapy group and 5.1 years for the intermittent treatment group. Men who received intermittent treatment initially reported better quality of life and mental health, but those gains were lost by the end of the study.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN